{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:46:21Z","timestamp":1790023581872,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.ygyno.2014.04.056","type":"journal-article","created":{"date-parts":[[2014,5,4]],"date-time":"2014-05-04T20:30:16Z","timestamp":1399235416000},"page":"10-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract\u2014A study of 24 cases from the Netherlands"],"prefix":"10.1016","volume":"134","author":[{"given":"Adriana C.H.","family":"van Engen-van Grunsven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi V.N.","family":"K\u00fcsters-Vandevelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"De Hullu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8140-387X","authenticated-orcid":false,"given":"Lucette M.","family":"van Duijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos","family":"Rijntjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith V.M.G.","family":"Bov\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia J.T.A.","family":"Groenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willeke A.M.","family":"Blokx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ygyno.2014.04.056_bb0005","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","article-title":"The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ygyno.2014.04.056_bb0010","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(08)70254-7","article-title":"Management of primary melanoma of the female urogenital tract","volume":"9","author":"Piura","year":"2008","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2014.04.056_bb0015","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejogrb.2004.11.048","article-title":"Primary malignant melanoma of the vagina: a case report and review of the current treatment options","volume":"121","author":"Gokaslan","year":"2005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"26","key":"10.1016\/j.ygyno.2014.04.056_bb0020","doi-asserted-by":"crossref","first-page":"4340","DOI":"10.1200\/JCO.2006.06.2984","article-title":"Somatic activation of KIT in distinct subtypes of melanoma","volume":"24","author":"Curtin","year":"2006","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ygyno.2014.04.056_bb0025","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ygyno.2014.04.056_bb0030","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/jid.2009.177","article-title":"Understanding melanoma signaling networks as the basis for molecular targeted therapy","volume":"130","author":"Smalley","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"26","key":"10.1016\/j.ygyno.2014.04.056_bb0035","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ygyno.2014.04.056_bb0040","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ygyno.2014.04.056_bb0045","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.bcp.2010.04.032","article-title":"Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics","volume":"80","author":"Woodman","year":"2010","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"10.1016\/j.ygyno.2014.04.056_bb0050","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.ejca.2012.02.049","article-title":"Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations","volume":"48","author":"Schoenewolf","year":"2012","journal-title":"Eur J Cancer"},{"issue":"22","key":"10.1016\/j.ygyno.2014.04.056_bb0055","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ygyno.2014.04.056_bb0060","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11912-012-0244-x","article-title":"Mucosal melanoma: pathogenesis, clinical behavior, and management","volume":"14","author":"Postow","year":"2012","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"10.1016\/j.ygyno.2014.04.056_bb0065","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2007.14.0707","article-title":"Major response to imatinib mesylate in KIT-mutated melanoma","volume":"26","author":"Hodi","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ygyno.2014.04.056_bb0070","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1755-148X.2008.00475.x","article-title":"Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation","volume":"21","author":"Lutzky","year":"2008","journal-title":"Pigment Cell Melanoma Res"},{"issue":"12","key":"10.1016\/j.ygyno.2014.04.056_bb0075","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/ncponc1251","article-title":"Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib","volume":"5","author":"Quintas-Cardama","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"issue":"17","key":"10.1016\/j.ygyno.2014.04.056_bb0080","first-page":"6483","article-title":"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression","volume":"9","author":"Omholt","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ygyno.2014.04.056_bb0085","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/jcp.2004.022509","article-title":"BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs","volume":"58","author":"Wong","year":"2005","journal-title":"J Clin Pathol"},{"issue":"7","key":"10.1016\/j.ygyno.2014.04.056_bb0090","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1128\/MCB.9.7.3114","article-title":"N-ras mutations in human cutaneous melanoma from sun-exposed body sites","volume":"9","author":"van 't Veer","year":"1989","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ygyno.2014.04.056_bb0095","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-3-642-78771-3_5","article-title":"Analysis of N-ras mutations in human cutaneous melanoma: tumor heterogeneity detected by polymerase chain reaction\/single-stranded conformation polymorphism analysis","volume":"139","author":"van Elsas","year":"1995","journal-title":"Recent Results Cancer Res"},{"issue":"4","key":"10.1016\/j.ygyno.2014.04.056_bb0100","doi-asserted-by":"crossref","first-page":"494","DOI":"10.18632\/oncotarget.970","article-title":"NRAS mutant melanoma\u2014undrugable?","volume":"4","author":"Posch","year":"2013","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.ygyno.2014.04.056_bb0105","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/sj.bjc.6605635","article-title":"Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT","volume":"102","author":"Handolias","year":"2010","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.ygyno.2014.04.056_bb0110","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1038\/sj.bjc.6604791","article-title":"Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas","volume":"99","author":"Satzger","year":"2008","journal-title":"Br J Cancer"},{"issue":"21","key":"10.1016\/j.ygyno.2014.04.056_bb0115","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":"KIT gene mutations and copy number in melanoma subtypes","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.ygyno.2014.04.056_bb0120","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1158\/1078-0432.CCR-10-2917","article-title":"KIT pathway alterations in mucosal melanomas of the vulva and other sites","volume":"17","author":"Omholt","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ygyno.2014.04.056_bb0125","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hed.23079","article-title":"Sinonasal mucosal melanoma: molecular profile and therapeutic implications from a series of 32 cases","volume":"35","author":"Turri-Zanoni","year":"2013","journal-title":"Head Neck"},{"issue":"2","key":"10.1016\/j.ygyno.2014.04.056_bb0130","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ijc.22681","article-title":"L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition","volume":"121","author":"Antonescu","year":"2007","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2014.04.056_bb0135","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00428-009-0762-6","article-title":"Esophageal melanomas harbor frequent NRAS mutations unlike melanomas of other mucosal sites","volume":"454","author":"Sekine","year":"2009","journal-title":"Virchows Arch"},{"issue":"26","key":"10.1016\/j.ygyno.2014.04.056_bb0140","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1200\/JCO.2012.47.7836","article-title":"Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin","volume":"31","author":"Hodi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ygyno.2014.04.056_bb0145","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1158\/1078-0432.CCR-11-1987","article-title":"Sunitinib therapy for melanoma patients with KIT mutations","volume":"18","author":"Minor","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ygyno.2014.04.056_bb0150","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/sj.jid.5700490","article-title":"Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations","volume":"127","author":"Bauer","year":"2007","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.ygyno.2014.04.056_bb0155","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/PPO.0b013e31824ba4df","article-title":"Targeting NRAS in melanoma","volume":"18","author":"Kelleher","year":"2012","journal-title":"Cancer J"},{"issue":"7074","key":"10.1016\/j.ygyno.2014.04.056_bb0160","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"Solit","year":"2006","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ygyno.2014.04.056_bb0165","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","article-title":"MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study","volume":"14","author":"Ascierto","year":"2013","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ygyno.2014.04.056_bb0170","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1073\/pnas.1216013110","article-title":"Combined targeting of MEK and PI3K\/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo","volume":"110","author":"Posch","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"10.1016\/j.ygyno.2014.04.056_bb0175","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.2010.33.9275","article-title":"Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification","volume":"29","author":"Guo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ygyno.2014.04.056_bb0180","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1535-7163.MCT-09-0459","article-title":"Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates","volume":"8","author":"Woodman","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.ygyno.2014.04.056_bb0185","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/path.2382","article-title":"Heterogeneity of kinase inhibitor resistance mechanisms in GIST","volume":"216","author":"Liegl","year":"2008","journal-title":"J Pathol"},{"issue":"6","key":"10.1016\/j.ygyno.2014.04.056_bb0190","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/CMR.0b013e32834bf398","article-title":"KIT mutations in Russian patients with mucosal melanoma","volume":"21","author":"Abysheva","year":"2011","journal-title":"Melanoma Res"},{"issue":"6","key":"10.1016\/j.ygyno.2014.04.056_bb0195","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1600-0463.2011.02737.x","article-title":"KIT amplification and gene mutations in acral\/mucosal melanoma in Korea","volume":"119","author":"Yun","year":"2011","journal-title":"APMIS"},{"issue":"11","key":"10.1016\/j.ygyno.2014.04.056_bb0200","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/modpathol.2009.116","article-title":"Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous\/mucosal type","volume":"22","author":"Torres-Cabala","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ygyno.2014.04.056_bb0205","doi-asserted-by":"crossref","DOI":"10.1038\/modpathol.2013.211","article-title":"Comparison of molecular abnormalities in vulvar and vaginal melanomas","author":"Aulmann","year":"2014","journal-title":"Mod Pathol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814009172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825814009172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T06:51:53Z","timestamp":1538635913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825814009172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0090825814009172"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.04.056","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract\u2014A study of 24 cases from the Netherlands","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2014.04.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}